Microtech to Unveil Implantable Microsensor Technology at 34th Annual Transcatheter Cardiovascular Therapeutics (TCT) Meeting

TEL AVIV, Israel, September 13, 2022 /PRNewswire/ — Microtech, a wholly owned subsidiary of Medinol, Inc., a leader in global MedTech research and development, announced that its implantable microsensor platform will be introduced at 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation on Friday, September 16. A prestigious selection, this session will highlight a limited number of cutting-edge technologies relevant to the advancement of cardiovascular treatment. Microtech is honored to be selected as one of the participating organizations.

Medinol logo

The Microtech implantable microsensor platform is the culmination of decades of development in a new class of sensor technology that can be used not only as a stand-alone device, but can also be integrated into any existing device turning it from a treatment-only device to a device intelligent data collection. able to perform several functions at the same time.

Session titled, “Microsensors: Transforming Implantable Devices into Real-Time Physiological Monitors (Microtech)” will present a procedure showing a device incorporating the Microtech implantable microsensor platform implanted in the left atrium for continuous assessment of heart failure. In addition to the presentation of the case, Dr. Yoram Richter Ph.D., CEO of Medinol Ltd, will present the technology platform followed by a Q&A with the guest panel and a panel discussion.

“Adding sensors to existing medical devices gives doctors the ability to treat patients based on measurable physiological parameters rather than symptoms and is a critical step in increasing access to equitable health care throughout the global community. Using a unit compact home, a patient with Microtech’s implantable microsensor platform can deliver immediate and highly accurate pressure readings directly to their physician, making the challenges of geographic distance or mobility a non-issue,” says Dr. Yoram Richter. “Since Microtech’s implantable microsensor platform can be used for various scenarios including patients suffering from heart failure, glaucoma, hydrocephalus, portal hypertension, AAA Endoleaks and many others, the integration, adoption and implantation of this innovative platform will provide broader access to health care and fewer office/hospital visits From the perspective of treating physicians and device manufacturers, sensor devices will go beyond acute anatomical adjustments, extending treatment into patient care throughout life .”

About Medinol

At Medinol, we are aggressively changing the paradigms of how disease states are diagnosed and treated. Whether designing cutting-edge devices for stenting multiple areas of the body, dramatically reducing complications in Structural Heart procedures, or providing real-time insights into physiological metrics of the human body through implantable sensors, we boldly re-evaluate technology and current procedures and look years into the future. to see new equipment to expand the reach of doctors both physically and geographically. Working with our physician and industry partners, Medinol is creating the future today.

For more information visit www.medinol.com or contact us Jeff RoachChief Commercial Officer at [email protected]

Cision

Cision

View original content to download multimedia: https://www.prnewswire.com/news-releases/microtech-to-unveil-implantable-microsensor-technology-at-34th-transcatheter-cardiovascular-therapeutics-tct-annual-meeting- 301621026 .html

SOURCE Medinol

Leave a Comment